Table 1 Diagnosis, disease duration, and number of ultrasound-guided SCG blocks of each case and changes in maximum NRS and analgesic consumption
Sex/age | Diagnosis | Disease duration (months) | Number of U-SCGB in 3 months | Maximum NRS before U-SCGB | Maximum NRS three months after starting U-SCGB | Analgesics per day before U-SCGB | Analgesics per day 3 months after starting U-SCGB | Increase/decrease of analgesics | |
|---|---|---|---|---|---|---|---|---|---|
1 | F/62 | PIFP | 36 | 3 | 5 | 7 | None | None | No change |
2 | F/32 | PIFP | 18 | 6 | 8 | 5 | Loxoprofen (120 mg), acetaminophen (3600 mg), pregabalin (50 mg) | Acetaminophen (1200 mg) | Decrease |
3 | F/34 | Occipital neuralgia | 6 | 3 | 4 | 1 | Loxoprofen (60 mg) | None | Decrease |
4 | F/35 | PPTTN | 4 | 4 | 4 | 1 | None | None | No change |
5 | F/45 | Occipital neuralgia | 14 | 5 | 9 | 5 | Carbamazepine (200 mg) | None | Decrease |
6 | F/65 | Burning mouth syndrome | 60 | 6 | 9 | 5 | Mirogabalin (20 mg), gabapentin (300 mg) | Mirogabalin (20 mg), gabapentin (300 mg) | No change |
7 | F/69 | PHTN | 3 | 4 | 8 | 3 | Pregabalin (75 mg) | Pregabalin (150 mg) | Increase |
8 | M/52 | PPTTN | 15 | 5 | 6 | 4 | Mirogabalin (20 mg) | Mirogabalin (20 mg) | No change |
9 | M/65 | Burning mouth syndrome | 24 | 3 | 8 | 8 | None | None | No change |
10 | F/54 | PHTN | 36 | 4 | 9 | 6 | Mirogabalin (5 mg) | Mirogabalin (5 mg) | No change |